DUET Study (2018) — Trial Summary

DUET Study (2018): Evaluated the efficacy of sparsentan, a dual endothelin and angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS).

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.